Mesoatrial Shunt for Budd-Chiari Syndrome.

Authors :: Zhu GC
Wang ZG
Bian C
Zhang JW
Hu ZW
Hou GF
Guo W
Ma C
Source :: Annals of vascular surgery [Ann Vasc Surg] 2018 Feb; Vol. 47, pp. 62-68. Date of Electronic Publication: 2017 Jul 21.
Publication Year :: 2018
Abstract: Background: The long-term efficacy of mesoatrial shunt (MAS) for Budd-Chiari syndrome (BCS) is not well studied. The purpose of our study was to investigate the long-term outcome and efficacy of MAS for BCS.<br />Methods: We retrospectively evaluated 11 patients who underwent MAS for BCS from April 1986 to November 1995. Records of patients' clinical presentations, laboratorial investigation, Doppler duplex ultrasonography, radiologic image, and treatment outcomes were all retrieved and analyzed.<br />Results: Follow-up intervals ranged from 1 year and 2 months to 30 years and 2 months (mean, 17 years and 8 months). Portal pressure decreased significantly from 35.72 ± 3.52 cm H <subscript>2</subscript> O to 27.86 ± 5.83 cm H <subscript>2</subscript> O post-MAS (P = 0.001). The 5-year, 10-year, and 20-year patency were 72.7%, 54.5%, 36.4%, respectively; 63.3% of patients had survived for more than 10 years and 45.5% for more than 20 years. A male has been alive with patent shunt for 28 years and 1 month.<br />Conclusions: The MAS with enforced rings is an effective therapeutic modality for BCS with cautious perioperative management.<br /> (Copyright © 2017 Elsevier Inc. All rights reserved.)